Pulse Biosciences Adds New Tech to PFA: Vanguards of Healthcare
Pulse Biosciences Adds New Tech to PFA
Vanguards of Healthcare
“As we've now begun to see with long-term results could potentially improve clinical outcomes because the effectiveness of the lesion creation, the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA” Pulse Biosciences’s CEO Paul LaViolette elaborates regarding the next stage of pulsed field ablation (PFA) innovation. In this Vanguards of Health Care episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation that combines an ultrashort pulse duration with a high amplitude of voltage. He dives further into the commercial strategy with initiation of its NANOPULSE-AF IDE pivotal study, after promising first in human trial results.
May 14, 2026